Associated Genetic Biomarkers
BAP1 Loss is present in 0.21% of AACR GENIE cases, with peritoneal mesothelioma, pleural epithelioid mesothelioma, breast invasive ductal carcinoma, small cell lung carcinoma, and pleural biphasic mesothelioma having the greatest prevalence .
BAP1 Loss serves as an inclusion eligibility criterion in 4 clinical trials, of which 3 are open and 1 is closed. Of the trials that contain BAP1 Loss as an inclusion criterion, 4 are phase 2 (3 open).
Trials with BAP1 Loss in the inclusion eligibility criteria most commonly target bladder carcinoma, malignant mesothelioma, melanoma, and urothelial carcinoma .
Olaparib and niraparib are the most frequent therapies in trials with BAP1 Loss as an inclusion criteria .
Significance of BAP1 Loss in Diseases
Malignant Mesothelioma +
BAP1 is altered in 34.94% of malignant mesothelioma patients with BAP1 Loss present in 8.58% of all malignant mesothelioma patients .
BAP1 Loss is an inclusion criterion in 2 clinical trials for malignant mesothelioma, of which 1 is open and 1 is closed. Of the trials that contain BAP1 Loss and malignant mesothelioma as inclusion criteria, 2 are phase 2 (1 open) .
Bladder Carcinoma +
Urothelial Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.